Optimization of a Decision Formula for Optimal Timing of Immunosuppressive Therapy Initiation in Primary Membranous Nephropathy: A Multicenter Retrospective Cohort Study

Yipeng Liu

Status: Active, not recruiting

Conditions: Primary Membranous Nephropathy

Study type: Observational

Funder types: Other

Identifiers

NCT06924476

YXLL-KY-2025(064)

Details and patient eligibility

About

The goal of this observational study is to optimize the evaluation formula for the timing of initiating immunosuppressive therapy in primary membranous nephropathy in patients with primary membranous nephropathy. The main question it aims to answer is:When should immunosuppressive therapy be initiated?This study is a retrospective one. Participants will not receive any treatment.

Enrollment: 282 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• It meets one of the diagnostic criteria for PMN as stipulated in the KDIGO 2021 Clinical Practice Guidelines for the Management of Glomerular Diseases: patients with a clear diagnosis of PMN based on renal biopsy pathology or presenting with nephrotic syndrome and positive anti-PLA2R antibody detection (>14RU/mL), and excluding secondary factors such as tumors, infections, drugs, and systemic autoimmune diseases.

Exclusion criteria

• (1) Patients who have received treatment with immunosuppressive medications other than oral prednisolone.

  (2) The time interval between the renal biopsy and the baseline measurement is longer than 3 years.

  (3) Initiate the use of immunosuppressive agents within 1 week after the diagnosis of PMN.

  (4) Participate in the immunosuppressive treatment trial during the follow-up period and be in the intervention group.

Trial design

282 participants in 2 patient groups

Modeling Group

Description:

The data of this group of participants are used to construct the evaluation formula.

Verification group

Description:

The data of this group of participants are used to verify the evaluation formula constructed through the modeling group.